GP2017: An Adalimumab Biosimilar.

Abstract

GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. GP2017 has similar physicochemical and functional properties to those of reference adalimumab, and the pharmacokinetic similarity of the agent has been shown in healthy male volunteers. GP2017 demonstrated clinical efficacy equivalent to that of reference adalimumab in patients with moderate to severe plaque psoriasis or rheumatoid arthritis; the tolerability, safety and immunogenicity profiles of the two agents were also similar. Multiple switching between GP2017 and reference adalimumab (up to four times) had no impact on efficacy, tolerability or immunogenicity. The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy.

• Authors: Young-A Heo
• Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (BioDrugs) Vol. 32 Issue 6 Pg. 635-638 (Dec 2018) ISSN: 1179-190X [Electronic] New Zealand
• PMID: 30460599 (Publication Type: Journal Article, Review)

Chemical References

• Biosimilar Pharmaceuticals
• GP2017
• TNF protein, human
• Tumor Necrosis Factor-alpha
• Adalimumab

Topics

• Adalimumab (pharmacology, therapeutic use)
• Autoimmune Diseases (drug therapy, immunology)
• Biosimilar Pharmaceuticals (pharmacology, therapeutic use)
• Drug Substitution
• Humans
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors, immunology)